SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

What are the specific PTM changes in synaptic vesicle proteins during early AD pathogenesis?

PARTIALLY ADDRESSED

The debate framework identified synaptic vesicle protein modifications as critical but no specific hypotheses were evaluated. Understanding which phosphorylation, ubiquitination, and glycosylation events drive synaptic dysfunction could reveal early therapeutic targets. Source: Debate session sess_SDA-2026-04-04-frontier-proteomics-1c3dba72 (Analysis: SDA-2026-04-04-frontier-proteomics-1c3dba72)

Priority: 0.88 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What are the specific PTM changes in synaptic vesicle proteins during early AD pathogenesis? is a 0.88 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What are the specific PTM changes in synaptic vesicle proteins during early AD pathogenesis? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-ros→ADentities-histone-methylation→ADentities-atp7b-gene→ADTAU→ADTDP-43→AD
▸ Show 16 more

biomarker for (1)

tau cleavage products→AD

causes (6)

AD→neurodegenerationPHOSPHORYLATED_TAU→ADBETA_AMYLOID→ADAD→IMMUNE_TOLAD→memory_loss
▸ Show 1 more

contributes to (1)

NEUROINFLAMMATION→AD

cross disease mechanism in (5)

MAPT→ADTREM2→ADNLRP3→ADPINK1→ADGRN→AD

depleted in (1)

SPM_levels→AD

prevents (1)

NAD+ augmentation→AD

protective against (1)

cognitive stimulation→AD

regulates (1)

AD→PROTEOME

risk factor for (4)

genetically at-risk individuals→ADAPOE ε4→ADmicroglial priming→ADAPOE4→AD

targets (1)

resveratrol→AD

therapeutic target for (6)

TREM2→ADCCR2→ADSaracatinib→ADanti-amyloid antibodies→ADNAD+ augmentation→AD
▸ Show 1 more

treats (1)

HTL9936→AD
🕑 Activity Feed
✏ update on knowledge_gap by None 2026-04-25T22:15
✏ update on knowledge_gap by None 2026-04-16T19:26
✏ update on knowledge_gap by None 2026-04-16T19:26
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps